Recent Price Movement and Market Context
On 18 Dec 2025, Concord Biotech’s stock price touched Rs.1318.85, its lowest level in the past year. This decline comes after two consecutive days of negative returns, with the stock losing approximately 3.91% over this period. Despite this, the stock marginally outperformed its sector by 0.42% on the day. However, it remains below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained downtrend.
In contrast, the broader market benchmark, the Sensex, opened flat and traded slightly lower by 0.12%, standing at 84,456.88 points. The Sensex remains close to its 52-week high of 86,159.02, just 2.02% away, and is supported by bullish moving averages with the 50-day DMA above the 200-day DMA. This divergence highlights the relative underperformance of Concord Biotech compared to the overall market.
Long-Term Performance and Valuation Metrics
Over the last year, Concord Biotech’s stock has recorded a return of -39.12%, significantly lagging behind the Sensex’s 5.36% gain during the same period. The stock’s 52-week high was Rs.2451.65, indicating a substantial reduction in market value over the past twelve months.
Financially, the company’s operating profit has shown a slight negative trend, with an annual rate of change of -0.48% over the last five years. Profit after tax (PAT) for the most recent quarter stood at Rs.63.58 crore, reflecting a decline of 28.6% compared to the average of the previous four quarters. Similarly, profit before tax (PBT) excluding other income was Rs.72.33 crore, down by 32.1% relative to the prior four-quarter average.
Operating cash flow for the year was recorded at Rs.244.52 crore, marking the lowest level in recent periods. These figures indicate subdued financial momentum in both profitability and cash generation.
Quarter after quarter, this Small Cap from the Lifestyle sector delivers without fail! Just added to our Reliable Performers with proven staying power. Stability meets growth here beautifully.
- - Consistent quarterly delivery
- - Proven staying power
- - Stability with growth
See the Consistent Performer →
Valuation and Efficiency Indicators
Concord Biotech’s return on equity (ROE) stands at 17.7%, reflecting a relatively high level of management efficiency in generating returns from shareholders’ equity. The stock’s price-to-book value ratio is 7.6, suggesting a valuation that is considered expensive when compared to its book value. However, this valuation aligns with the average historical valuations observed among its peer group within the Pharmaceuticals & Biotechnology sector.
The company maintains a low debt-to-equity ratio, averaging zero, indicating minimal reliance on borrowed funds and a conservative capital structure. Promoters hold the majority shareholding, which may influence strategic decisions and long-term company direction.
Comparative Performance and Sector Positioning
In addition to its one-year underperformance relative to the Sensex, Concord Biotech has also lagged behind the BSE500 index over the last three years, one year, and three months. This below-par performance in both the near and long term highlights challenges in maintaining competitive growth within the Pharmaceuticals & Biotechnology sector.
While the broader market indices have shown resilience and positive momentum, Concord Biotech’s stock has struggled to keep pace, reflecting sector-specific pressures and company-level factors.
Is Concord Biotech your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Financial Indicators
To summarise, Concord Biotech’s recent financial data presents a mixed picture. The company’s quarterly profit metrics show declines relative to recent averages, while cash flow generation is at a low point. The stock’s valuation remains elevated relative to book value, despite subdued profit growth over the past year.
Management efficiency, as indicated by ROE, remains strong, and the company’s capital structure is conservative with negligible debt. These factors provide some stability amid the stock’s recent price weakness.
Stock Price and Market Sentiment
The stock’s fall to Rs.1318.85 represents a significant technical milestone, marking the lowest price level in the past 52 weeks. This level is substantially below the stock’s 52-week high of Rs.2451.65, underscoring the extent of the price correction over the year.
Despite the broader market’s positive trend, Concord Biotech’s share price has not mirrored this momentum, reflecting company-specific developments and sector dynamics within Pharmaceuticals & Biotechnology.
Ownership and Capital Structure
Promoters continue to hold the majority stake in Concord Biotech, maintaining control over strategic decisions. The company’s low debt profile further supports a stable financial footing, reducing exposure to interest rate fluctuations and credit risk.
Conclusion
Concord Biotech’s stock reaching a 52-week low of Rs.1318.85 highlights ongoing challenges in the company’s financial performance and market valuation. While management efficiency and capital structure remain positive attributes, the stock’s price action and profit trends indicate a cautious environment for the company within the Pharmaceuticals & Biotechnology sector.
Only Rs. 14,999 - Get MojoOne + Stock of the Week for 1 Year PLUS 18 Months FREE! Claim Your Free Year →
